AKERO THERAPEUTICS INC

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Akero’s lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, and SYNCHRONY Real-World in patients with MASH or MASLD (metabolic dysfunction-associated steatotic liver disease). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. Akero is headquartered in South San Francisco. Visit us at Akerotx.com and follow us on LinkedIn and X for more information.

1. SCHEDULE 13G/A - filed by JANUS HENDERSON GROUP PLC regarding Akero Therapeutics, Inc.Feb 17, 2026
2. SCHEDULE 13G/A - filed by RTW INVESTMENTS, LP regarding Akero Therapeutics, Inc.Feb 17, 2026
3. SCHEDULE 13G/A - filed by Deep Track Capital, LP regarding Akero Therapeutics, Inc.Feb 13, 2026
4. 15-12G filingDec 19, 2025
5. 25-NSE - filed by Nasdaq Stock Market LLC regarding Akero Therapeutics, Inc.Dec 9, 2025